Summary
Project Summary/Abstract When the API Autosomal Dominant Alzheimer's Disease (ADAD) Colombia Trial (NCT01998841) was announced in 2012, it launched a new era in AD prevention research. The trial led us to identify ~6,000 persons from the world's largest ADAD kindred, including nearly 1,200 presenilin 1 (PSEN1) E280A mutation carriers, who are virtually certain to develop AD and become cognitively impaired at 44 (SD ± 5) years of age; establish the clinical trials, infusion capability, PET, and MRI infrastructure Colombia needed to conduct interventional studies in the kindred; and introduce pr
